• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Polycystic Ovarian Syndrome - Pipeline Review, H1 2012 Product Image

Polycystic Ovarian Syndrome - Pipeline Review, H1 2012

  • Published: February 2012
  • 48 pages
  • Global Markets Direct

Polycystic Ovarian Syndrome – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012', provides an overview of the Polycystic Ovarian Syndrome therapeutic pipeline. This report provides information on the therapeutic development for Polycystic Ovarian Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Polycystic Ovarian Syndrome. 'Polycystic Ovarian Syndrome - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Polycystic Ovarian Syndrome.
- A review of the Polycystic Ovarian READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Polycystic Ovarian Syndrome Overview
Therapeutics Development
An Overview of Pipeline Products for Polycystic Ovarian Syndrome
Polycystic Ovarian Syndrome Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Polycystic Ovarian Syndrome Therapeutics – Products under Investigation by Universities/Institutes
Polycystic Ovarian Syndrome – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
OCP - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Raloxifene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Letrozole - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Chorionic Gonadotropin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Human Chorionic Gonadotropin + Clomiphene Citrate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aldactone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
D-chiro-inositol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Simvastatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Dexamethasone + Recombinant hCG - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin + Clomiphene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Tamoxifen + Clomiphene - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Flutamide + Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Clomiphene Citrate + Dexamethasone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Medroxyprogesterone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Metformin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Aspirin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Polycystic Ovarian Syndrome Therapeutics – Drug Profile Updates
Polycystic Ovarian Syndrome Therapeutics - Dormant Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Polycystic Ovarian Syndrome, H1 2012
Products under Development for Polycystic Ovarian Syndrome – Comparative Analysis, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Polycystic Ovarian Syndrome Therapeutics – Drug Profile Updates
Polycystic Ovarian Syndrome Therapeutics – Dormant Products

List of Figures
Number of Products under Development for Polycystic Ovarian Syndrome, H1 2012
Products under Development for Polycystic Ovarian Syndrome – Comparative Analysis, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos